Rivian Automotive Inc. (NASDAQ:RIVN) Secures First Deal with AT&T Inc (NYSE:T) in Growing Electric Vehicle Market\n\nRivian Automotive Inc. has recently announced its first deal with AT&T Inc. , marking a significant move in its business strategy. This deal comes after the company ended its exclusive partnership with Amazon.com Inc. (NASDAQ:AMZN), showcasing Rivian’s growing demand and success in the electric vehicle market.\n\nAT&T, a company committed to sustainability, has chosen to enrich its fleet with Rivian’s electric commercial vans, R1T pickup trucks, and R1S sport utility vehicles. While the exact number of vehicles and financial terms were not disclosed, this deal is a testament to both companies’ efforts to reduce costs, cut carbon emissions, and improve safety.\n\nRivian’s increased demand for its electric vehicles is evident as it recently raised its 2023 production target to 54,000 units. The company also confirmed its commitment to Amazon, with plans to deliver 100,000 electric vans by the end of the decade. Facing competition from other EV makers, such as Tesla Inc (NASDAQ:TSLA) and Ford Motor (NYSE:F), Rivian remains confident in its ability to succeed in the market.\n\nWhile Tesla’s Cybertruck may pose a challenge to Rivian’s electric pickup, the company sees it as an opportunity in disguise. With Tesla’s unique design and lower starting price, it could potentially attract a different market segment, leaving room for Rivian to thrive in its own niche.\n\nIn a Rivian’s first deal with AT&T is a significant milestone for the company, highlighting its value and potential in the electric vehicle market.

Moderna (MRNA) Shares Rise on Positive Trial Results and CDC Alert for Increased Immunization Coverage\n\nModerna (MRNA) shares saw a significant increase of over 9% on Thursday following positive trial results for a collaborative skin cancer treatment with Merck (MRK). This treatment combines a vaccine with the drug Keytruda. In contrast, Pfizer (PFE) disappointed investors this week with its 2024 guidance. Yahoo Finance Health Reporter Anjalee Khemlani provides expert insight and highlights the top stories and biggest drivers behind pharmaceutical stocks on Thursday.\n\nThe U.S. Centers for Disease Control and Prevention (CDC) issued an alert on Thursday urging healthcare providers to increase immunization coverage for influenza, COVID-19, and respiratory syncytial virus (RSV). The CDC expressed concern over low vaccination rates and the potential for increased disease severity and strain on healthcare capacity in the coming weeks. They recommend antiviral medications for influenza and COVID-19 for all eligible patients, particularly older adults and those with underlying medical conditions.\n\nAccording to CDC data, hospitalizations for influenza, COVID-19, and RSV have increased significantly in the past four weeks, with a 200% increase for influenza, 51% for COVID-19, and 60% for RSV. The CDC also reported a decrease of 7.4 million influenza vaccine doses administered to adults compared to the previous season. There has been an increase in RSV and COVID-19 vaccinations among adults aged 60 and above, with 16% and 36% respectively.\n\nPfizer, Moderna, and Novavax have all developed COVID-19 vaccines that are approved in the United States, with Pfizer also having an approved RSV vaccine. This news comes as the Dow Jones index reached another high, although the market weakened in afternoon trading. CAT stock saw a jump in response to this news.\n\n Moderna's positive trial results and Pfizer's disappointing guidance have been the main drivers behind the pharmaceutical market on Thursday.